Suk-Hyung Kwon
Chief Executive Officer at NOVAREX CO.,LTD.
Net worth: 24 M $ as of 2024-03-30
Profile
Suk-Hyung Kwon is currently the Chairman & Chief Executive Officer at NOVAREX Co., Ltd.
since 2019.
He is also the Chief Executive Officer at NOVAKMED since 2017 and the Chairman of the Korea Health Supplements Association since 2016.
Additionally, Dr. Kwon is a Senior Associate at STIC Investments, Inc. (South Korea).
Previously, he worked as a Director at Rexahn Pharmaceuticals, Inc. from 2001 to 2005.
Dr. Kwon holds a doctorate degree from Chung-Ang University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NOVAREX CO., LTD.
17.83% | 2023-11-14 | 3,344,214 ( 17.83% ) | 24 M $ | 2024-03-30 |
Suk-Hyung Kwon active positions
| Companies | Position | Start |
|---|---|---|
| NOVAREX CO.,LTD. | Chief Executive Officer | 2019-03-21 |
| NOVAKMED | Chief Executive Officer | 2017-01-01 |
| Korea Health Supplements Association | Chairman | 2016-02-24 |
STIC Investments, Inc. (South Korea)
 STIC Investments, Inc. (South Korea) Investment ManagersFinance STIC Investments, Inc. (South Korea) is a private equity subsidiary of STIC Investments, Inc. founded in 1999 by Yong-Hwan Do and Byung-Won Choi. STIC Investments, Inc. (South Korea) is headquartered in Seoul, South Korea. | Private Equity Analyst | - |
Former positions of Suk-Hyung Kwon
| Companies | Position | End |
|---|---|---|
| REXAHN PHARMACEUTICALS, INC. | Director/Board Member | 2005-06-13 |
Training of Suk-Hyung Kwon
| Chung-Ang University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NOVAREX CO.,LTD. | Health Technology |
| Private companies | 4 |
|---|---|
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
STIC Investments, Inc. (South Korea)
STIC Investments, Inc. (South Korea) Investment ManagersFinance STIC Investments, Inc. (South Korea) is a private equity subsidiary of STIC Investments, Inc. founded in 1999 by Yong-Hwan Do and Byung-Won Choi. STIC Investments, Inc. (South Korea) is headquartered in Seoul, South Korea. | Finance |
| Korea Health Supplements Association | |
| NOVAKMED |
- Stock Market
- Insiders
- Suk-Hyung Kwon
